Pfizer Inc. (NYSE: PFE) shares stumbled Tuesday, after the drug concern came out with fourth-quarter and full-year figures.
The New York-based Pfizer said full-Year 2019 Revenues of $51.8 Billion, Reflecting 1% Operational Decline; Excluding the Impact from Consumer Healthcare, Revenues Increased 2% Operationally.
The news release from Tuesday also noted 8% Operational Growth from Biopharma, Primarily Driven by Ibrance, Eliquis, Xeljanz and Vyndaqel as well as 14% Operational Growth in Emerging Markets
There was, however, a 16% operational decline from Upjohn, Primarily Due to U.S. loss of exclusivity of Lyrica in 2019. Fourth-quarter revenues were $12.7 Billion, reflecting 8% operational decline; excluding the Impact from Consumer Healthcare(. Revenues declined 1% operationally
Full-year figures consisted of a diluted EPS of $2.87, adjusted diluted EPS of $2.95.
The company also provided Full-Year 2020 Financial Guidance for Total Company( New Pfizer and Upjohn.
Total company revenue guidance of $48.5 to $50.5 Billion. Adjusted diluted EPS of $2.82 to $2.92.
Acquisitions and the contribution of Pfizer’s Consumer Healthcare business to the GSK Consumer Healthcare joint venture (JV) that were completed during 2019 impacted financial results in the periods presented.
Shares gave back $1.28, or 3.2%, to $38.88
